Patent ID: 11872236
Assignee: CALASIA PHARMACEUTICALS, INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC A | IPC A

Claim 0:
1. A method for treating presbyopia or cataract in a subject in need thereof, the method comprising administering to the subject an effective amount of a composition comprising, as a sole active agent, a compound having formula (VII):, or a solvate or a pharmaceutically acceptable salt thereof, wherein
R1 is independently selected from the group consisting of hydrogen; (C1-C3)alkyl; halo(C1-C3)alkyl; (C3-C6)cycloalkyl; halo(C3-C6)cycloalkyl; (C1-C3)alkyloxy; and R4C═O; wherein R4 is selected from the (C1-C6)alkyl; halo(C1-C6)alkyl; (C3-C6)cycloalkyl; halo(C3-C6)cycloalkyl; aryl; haloareyl; and, , wherein R7 is (C1-C6)alkyl and R8 is (C1-C6)alkyl, aryl, or a polyethylene glycol group;
R2 is independently selected from the group consisting of hydrogen, R5, OR5, N(R5)(R6), halide, CN, NO2, C(O)OR5, CON(R5)(R6), S(O)NR52, SO3H, SO2CH3, phenyl, biphenyl, phenoxy-phenyl, and polyethyleneglycol groups, wherein R5 and R6 are independently selected from hydrogen atom, (C1-C6)alkyl, halo(C1-C6)alkyl, (C3-C6)cycloalkyl, halo(C3-C6)cycloalkyl, (C3-C6)cycloalkyl(C1-C6)alkyl, halo(C3-C6)cycloalkyl(C1-C6)alkyl, and (C3-C6)cycloalkylhalo(C1-C6)alkyl groups; wherein R2 can occupy 0-2 positions in the ring of its occurrence; and wherein, in the event any two adjacent groups selected are OR5 groups, the two OR5 groups may optionally be cross-linked via their R5 functionalities to form an additional ring; and
R3 is selected from the group consisting of hydrogen, (C1-C6)alkyl, halo(C1-C6)alkyl, (C3-C6)cycloalkyl, halo(C3-C6)cycloalkyl, (C2-C6)alkenyl, halo(C2-C6)alkenyl, and hydroxy(C2-C6)alkenyl, and
wherein the method is free of a step of administering a second active agent.